ViiV Healthcare announces positive Week 48 results in first study to evaluate treatment switch from TAF-containing regimen with three or more drugs to 2-drug regimen of dolutegravir/lamivudine for HIV-1 infection - Yahoo Finance

ViiV Healthcare announces positive Week 48 results in first study to evaluate treatment switch from TAF-containing regimen with three or more drugs to 2-drug regimen of dolutegravir/lamivudine for HIV-1 infection  Yahoo Finance

Today ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders, announced that data ...



Comments

Popular posts from this blog

Is Citronella Safe for Dogs? A Veterinarian Provides Guidance

Everything You Need to Know About Mite and Flea Bites

The Best Flea Treatments for Cats and Dogs